Solana Company (HSDT) reported QQ3 2024 results that underscore a pre-revenue, early-stage healthcare device company with a single-quarter revenue of $51,000 and an overall net loss of $3.69 million. The quarter featured a negative gross margin of -2.67% as cost of revenue exceeded revenue by $136,000, driven by high research and development (R&D) spend and selling/general administration (SG&A) expense that remains elevated relative to topline activity. EBITDA was negative $4.054 million and net income registered at -$3.686 million, translating to an EPS of -$0.99 on 3.74 million weighted-average shares. Despite a modest cash cushion of $3.47 million at quarter-end and only a small short-term debt load, Solana’s liquidity is fragile given operating cash flow of -$2.77 million for the quarter and a working capital profile that yields extended receivables and inventory days. The company’s accumulated deficit remains substantial, and management commentary (where available) is not included in the provided dataset, leaving the investment thesis highly contingent on future catalysts such as clinical data, regulatory milestones, or potential licensing agreements.
Near term implications: Solana’s revenue trajectory and profitability remain binary until the company can monetize its platform via licensing or strategic partnerships. The current burn rate implies a limited runway without external financing or revenue accretion. Long term, the opportunity rests on the commercialization potential of a noninvasive tongue-based neuromodulation platform, but execution risk is high given the current quarterly results and negligible near-term revenue growth.
Profitability and operating metrics:
- R&D expenses: $1.077 million; SG&A expenses: $2.85 million; other operating items: $7,000; operating expenses: $3.934 million; total cost and expenses: $4.121 million
- EBITDA: -$4.054 million; EBITDA margin: -79.49%
- Operating income: -$4.07 million; operating margin: -79.80%
- Net income: -$3.686 million; net margin: -72.27%; EPS: -$0.99
Cash flow and liquidity:
- Net cash provided by operating activities: -$2.771 million; free cash flow: -$2.771 million
- Cash at end of period: $3.468 million; cash at beginning: $6.387 million; net change in cash: -$2.919 million; minority forex impact: +$1,000
Balance sheet and leverage:
- Total assets: $5.585 million; total liabilities: $1.787 million; total stockholders’ equity: $3.799 million
- Short-term debt: $46,000; total debt: $23,000; net debt: -$3.445 million (net cash position)
- Retained earnings: -$167.771 million; accumulated other comprehensive income/loss: -$0.427 million
Key efficiency and liquidity ratios:
- Current ratio: 3.61; quick ratio: 2.87; cash ratio: 2.32
- Asset turnover: 0.009; receivables turnover: 0.0973; inventory turnover: 0.169; CCC: ~1,458 days
- Price/book value: 8.29; price/sales: 617.57; enterprise value multiple: -6.92
Compared with peers (selected):
- Gross margins across peers vary; IRIX shows gross margin around 0.373 and more favorable profitability metrics, while HSDT shows a negative gross margin and substantial operating losses. Valuation multiples for HSDT (P/S ~ 618x) are markedly higher-than peers like IRIX (P/S ~ 2.56x) and QNRX (P/S ~ 0x–0.0x in the provided data), underscoring the speculative nature of the stock given minimal current revenue.
Income Statement
Metric
Value
YoY Change
QoQ Change
Revenue
51.00K
-64.34%
-71.98%
Gross Profit
-136.00K
-78.95%
-312.50%
Operating Income
-4.07M
-35.94%
-24.46%
Net Income
-3.69M
-0.63%
-128.66%
EPS
-0.99
81.97%
-54.69%
Key Financial Ratios
Gross Profit Margin
Weak
-2.67%
Gross profit margin is below industry norms, profitability concerns
Operating Profit Margin
Weak
-79.80%
Operating margin is below industry norms, profitability concerns
Net Profit Margin
Weak
-72.27%
Net profit margin is below industry norms, profitability concerns
Return on Assets
Weak
-0.66%
Return on assets suggests inefficient capital allocation
Return on Equity
Weak
-0.97%
Return on equity suggests inefficient capital allocation
Current Ratio
Strong
3.61
Current ratio indicates excellent liquidity and financial flexibility
Debt to Equity
Conservative
0.01
Debt-to-equity shows conservative leverage and low financial risk
P/E Ratio
Negative
-2.14x
Negative earnings make P/E ratio not meaningful
Price to Book
High Premium
8.29x
Very high premium suggests asset-light business model or lofty expectations
Management Insights Available for Members
Get exclusive access to management commentary, earnings call quotes, and forward guidance from company leadership.
Solana Company (HSDT) QQ1 2026 Financial Analysis – Healthcare/Medical Devices: Early Traction with High Cash Burn in a Pre-Commercial Neon Neuromod...
Solana Company (HSDT) QQ2 2024 Earnings Analysis: Medicare and VA Reimbursement Milestones Drive Near-Term Turnaround Prospects in Neurotech Medical D...